What is the Morepen Laboratories PE ratio today?
Morepen Laboratories' PE ratio is 34.7 at the 29 October 2026 close (₹119.31 a share): a market capitalisation of ₹6,537 crore divided by consolidated net profit of ₹189 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹94.9 crore) it is 68.9.
What is the Morepen Laboratories net worth?
Morepen Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,381 crore on 30 September 2026, up 15.5% from ₹1,196 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹6,537 crore at the 29 October 2026 close.
What is the Morepen Laboratories book value per share?
Morepen Laboratories' book value per share was ₹25.21 on 30 September 2026: shareholders' equity of ₹1,381 crore divided by the 54.79 crore shares in issue, up 15.5% from ₹21.83 a year earlier. The share price at the 29 October 2026 close was ₹119.31.
What is the Morepen Laboratories PB ratio (price to book value)?
Morepen Laboratories' price-to-book (PB) ratio is 4.73 at the 29 October 2026 close: a market capitalisation of ₹6,537 crore divided by shareholders' equity (book value) of ₹1,381 crore on 30 September 2026. That is a book value of ₹25.21 per share against a share price of ₹119.31.
What is the Morepen Laboratories ROE and ROCE?
In FY26, Morepen Laboratories' return on equity (ROE) was 7.9% and its return on capital employed (ROCE) was 6.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.8% and ROCE 13.4%.
What is the Morepen Laboratories dividend yield?
Morepen Laboratories' dividend yield is 0.17% at the 29 October 2026 close: dividends of ₹0.20 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹119.31. They were ₹0.20 on 18 September 2026.
What is the Morepen Laboratories market cap?
Morepen Laboratories' market capitalisation was ₹6,537 crore at the 29 October 2026 close: 54.79 crore shares at ₹119.31 each.
Is Morepen Laboratories debt free?
No. Morepen Laboratories had borrowings of ₹305 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.22. Its cash and current investments were ₹271 crore, so its net debt was ₹34 crore.
What is the Morepen Laboratories EPS?
Morepen Laboratories' basic earnings per share (EPS) were ₹1.73 in FY26, against ₹2.20 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹3.43.
What is the Morepen Laboratories debt to equity ratio?
Morepen Laboratories' debt-to-equity ratio was 0.22 on 30 September 2026: borrowings of ₹305 crore against total equity of ₹1,382 crore. A year earlier, on 30 September 2025, it was 0.12.
What is the Morepen Laboratories dividend in 2026 and its record date?
In 2026, Morepen Laboratories has declared one dividend: ₹0.20 with record date 19 September 2026 and ex-date 18 September 2026.
What is the Morepen Laboratories promoter holding?
Promoters held 35.65% of Morepen Laboratories on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Morepen Laboratories shareholding pattern?
On 30 September 2026, Morepen Laboratories' shares were held by promoters 35.65%, foreign portfolio investors (FII/FPI) 3.43%, domestic institutions (DII) 1.71% (including mutual funds at 0.00%) and retail and other non-institutional investors 59.19%. Over the year, FII holding was up 1.81 percentage points from 1.62% and DII holding was up 0.21 percentage points from 1.50%.
How does Morepen Laboratories compare with its peers?
On FY26 consolidated figures, against IOL Chemicals and Pharmaceuticals, Innova Captab and FDC: Morepen Laboratories' operating margin of 4.9% is the lowest of the four (IOL Chemicals and Pharmaceuticals 8.1%, Innova Captab 12.1%, FDC 13.2%; peer average 11.2%); its return on equity of 7.9% is the third highest of the four (IOL Chemicals and Pharmaceuticals 7.9%, Innova Captab 14.0%, FDC 11.8%; peer average 11.2%).
How does the Morepen Laboratories PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Morepen Laboratories' PE ratio is 68.9, the highest of the four: IOL Chemicals and Pharmaceuticals 39.4, Innova Captab 42.0 and FDC 21.8, a peer average of 34.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Morepen Laboratories free cash flow?
In FY26, Morepen Laboratories generated ₹32.6 crore of cash from operations and spent ₹161 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹128 crore. In FY25 it was −₹182 crore.
What are the Morepen Laboratories latest quarterly results?
Morepen Laboratories' latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit ₹88.9 crore, up 117.5% from ₹40.9 crore in Q2 FY26; revenue from operations ₹747 crore, up 81.4% year on year.
What is the Morepen Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Morepen Laboratories' consolidated net profit was ₹94.9 crore, down 19.6% from ₹118 crore in FY25, on revenue from operations of ₹1,806 crore (down 0.3%). Over three years, from FY23, net profit was up 145.3%.
When are the Morepen Laboratories next results?
Morepen Laboratories has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Morepen Laboratories vs IOL Chemicals and Pharmaceuticals: how do they compare?
In FY26, Morepen Laboratories earned net profit of ₹94.9 crore on revenue of ₹1,806 crore, against ₹138 crore on ₹2,319 crore for IOL Chemicals and Pharmaceuticals. Morepen Laboratories' operating margin was 4.9% (IOL Chemicals and Pharmaceuticals 8.1%) and its return on equity 7.9% (IOL Chemicals and Pharmaceuticals 7.9%). At the 29 October 2026 close, Morepen Laboratories' market capitalisation was ₹6,537 crore against ₹5,429 crore for IOL Chemicals and Pharmaceuticals, and its PE ratio on FY26 profit 68.9 against 39.4.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
